

# **NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/N2812C3577FEN.html>

Date: July 2018

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: N2812C3577FEN

## **Abstracts**

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018

### **SUMMARY**

According to the recently published report 'NT 3 Growth Factor Receptor - Pipeline Review, H2 2018'; NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules.

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Tropomyosin receptor kinase C (TrkC) or NT-3 growth factor receptor is a protein encoded by the NTRK3 gene. It is involved in nervous system and probably heart development. Upon binding of its ligand neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the AKT and the MAPK pathways that control cell survival and differentiation.

The report 'NT 3 Growth Factor Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule

type; that are being developed by Companies/Universities.

It also reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 1 respectively.

Report covers products from therapy areas Oncology, Central Nervous System and Genetic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Fibrosarcoma, Neuroblastoma, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Biliary Tumor, Brain Tumor, Cancer Pain, Cervical Cancer, Charcot-Marie-Tooth Disease, Gastrointestinal Stromal Tumor (GIST), Glioma, Head And Neck Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Synovial Sarcoma and Thyroid Cancer.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)

The report reviews NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics under development by companies and

universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Overview

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Handok Inc

Ignyta Inc

Loxo Oncology Inc

Plexxikon Inc

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles

AZD-7451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-6051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-22B10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Products

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jun 04, 2018: NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

May 29, 2018: U.S. FDA accepts larotrectinib New Drug Application and grants priority review

May 17, 2018: Bayer Provides Update on larotrectinib at ASCO 2018

Mar 26, 2018: Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer

Feb 21, 2018: Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

Dec 20, 2017: Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers

Dec 20, 2017: Loxo Oncology Initiates Rolling Submission of New Drug Application to

## U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers

Dec 07, 2017: Bayer to Highlight New Oncology Research on larotrectinib at ASH 2017

Dec 04, 2017: Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers

Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors

Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients with ROS1-Positive Non-Small Cell Lung Cancer

Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer

Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Products under Development by Companies, H2 2018 (Contd.3), H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by AstraZeneca Plc, H2 2018  
Pipeline by Daiichi Sankyo Co Ltd, H2 2018  
Pipeline by Handok Inc, H2 2018  
Pipeline by Ignyta Inc, H2 2018  
Pipeline by Loxo Oncology Inc, H2 2018  
Pipeline by Plexxikon Inc, H2 2018  
Dormant Projects, H2 2018  
Discontinued Products, H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

### COMPANIES MENTIONED

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Handok Inc

Ignyta Inc

Loxo Oncology Inc

Plexxikon Inc

## I would like to order

Product name: NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/N2812C3577FEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N2812C3577FEN.html>